WHO ICTRP trial
A PHASE III CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-1293 COMPARED…
PER-059-13 · Registro Peruano de Ensayos Clínicos (REPEC)
Key facts
| Trial ID | PER-059-13 |
|---|---|
| Public title | A PHASE III CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-1293 COMPARED TO LANTUS™ IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
| Scientific title | A PHASE III CLINICAL TRIAL TO STUDY THE SAFETY AND EFFICACY OF MK-1293 COMPARED TO LANTUS™ IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS |
| Primary sponsor | Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., |
| Registry | Registro Peruano de Ensayos Clínicos (REPEC) |
| Study type | Interventional |
| Phase | III |
| Countries | Australia;New Zealand;South Africa;Colombia;Mexico;United States |
| Conditions | -E11 Non-insulin-dependent diabetes mellitus Non-insulin-dependent diabetes mellitus;E11 ;Non-insulin-dependent diabetes mellitus |
| Interventions | Solution for injection sterile, clear, colorless, which has preservatives and comes as insulin U 100, which contains 100 units of insulin glargine per milliliter (1 mL = 1 cc) |
| Registration date | Feb 27, 2014 |
| Target size | 60 |
| Registry page | ins.gob.pe |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: